Bolt Biotherapeutics (NASDAQ:BOLT) Posts Quarterly Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) issued its earnings results on Tuesday. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46), FiscalAI reports. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $1.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 91.06%.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ:BOLT traded down $0.01 during midday trading on Thursday, reaching $4.82. 15,492 shares of the company traded hands, compared to its average volume of 25,310. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.76. Bolt Biotherapeutics has a 12 month low of $3.91 and a 12 month high of $9.25. The firm has a market capitalization of $9.26 million, a price-to-earnings ratio of -0.30 and a beta of 1.10. The firm’s fifty day moving average price is $4.59 and its two-hundred day moving average price is $5.13.

Analysts Set New Price Targets

BOLT has been the topic of several research reports. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research note on Friday, March 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $41.00.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC grew its position in Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares in the last quarter. Shay Capital LLC purchased a new position in Bolt Biotherapeutics during the third quarter worth about $85,000. Susquehanna International Group LLP purchased a new position in Bolt Biotherapeutics during the third quarter worth about $89,000. Finally, Renaissance Technologies LLC grew its position in Bolt Biotherapeutics by 92.2% during the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after buying an additional 26,400 shares in the last quarter. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.